<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083173</url>
  </required_header>
  <id_info>
    <org_study_id>P11-068</org_study_id>
    <nct_id>NCT01083173</nct_id>
  </id_info>
  <brief_title>Surveillance of Kaletra in Korean Patients</brief_title>
  <official_title>Post-Marketing Surveillance of Safety and Efficacy of KaletraÂ® Tablet in Korean Patients Under the &quot;New Drug Re-Examination&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-arm, multi-center, Post-Marketing Surveillance study of Kaletra
      (lopinavir/ritonavir) was conducted in accordance with the approved Korean product labeling
      in participants 2 years of age and older with human immunodeficiency virus type 1 (HIV-1)
      infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were observed for up to 48 weeks following the first dose of Kaletra. A
      follow-up visit took place 1-2 weeks after treatment initiation, and subsequent visits
      occurred at the discretion of the investigators, typically occurring every 3 months.
      Clinical/immunological/virological/laboratory status, Kaletra-containing regimen/concomitant
      medication information, and adverse event information were obtained at follow-up visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From the start of treatment until 30 days after the last dose, up to 52 weeks</time_frame>
    <description>Adverse events were recorded during the 48-week surveillance period and until 30 days following the last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Interrupted or Discontinued Kaletra Treatment</measure>
    <time_frame>Weeks 24 and 48 after initiation of Kaletra treatment or upon permanent discontinuation of Kaletra treatment</time_frame>
    <description>At 24 and 48 weeks after initiation of Kaletra treatment or upon permanent discontinuation of Kaletra treatment, the investigator documented Kaletra status (on-going, permanently discontinued, lost to follow-up, etc).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Viral Load Below 400 Copies/mL</measure>
    <time_frame>Week 24</time_frame>
    <description>Blood samples were obtained from participants 24 weeks after the start of Kaletra treatment, and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Viral Load Below 50 Copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Blood samples were obtained from participants 48 weeks after the start of Kaletra treatment, and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Viral Load</measure>
    <time_frame>Week 24 &amp; 48</time_frame>
    <description>This variable, change from baseline in viral load, was not included in the final protocol. Therefore, these data were not calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Counts</measure>
    <time_frame>From baseline to Weeks 24 and 48</time_frame>
    <description>Blood samples were obtained from participants at baseline, 24, and 48 weeks after the start of Kaletra treatment and analyzed for CD4 cell counts. Change in CD4 cell counts in the main surveillance population was calculated by subtracting the value at baseline from the value at 24 weeks. Change in CD4 cell counts in the long-term surveillance population was calculated by subtracting the value at baseline from the value at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Confirmed Viral Resistance</measure>
    <time_frame>From baseline through weeks 24 and 48</time_frame>
    <description>Blood samples were obtained from participants at initiation of Kaletra treatment and follow up visits through weeks 24 and 48 and analyzed for genotypic viral resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time to Treatment Failure</measure>
    <time_frame>From baseline through weeks 24 and 48</time_frame>
    <description>Blood samples were obtained from participants at initiation of Kaletra treatment and at follow up visits through weeks 24 and 48 and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels. Treatment failure was defined as HIV RNA level &gt; 400 copies/mL at week 24 and HIV RNA level &gt; 50 copies/mL at week 48.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">595</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Participants with HIV-1 infection</arm_group_label>
    <description>Participants treated with Kaletra (lopinavir/ritonavir 200 mg/50 mg and 100 mg/25 mg) tablet</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        general hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 2 years of age and above with HIV-1 infection

          -  Patients who were prescribed Kaletra treatment as per investigator's medical judgment

          -  Patients who gave verbal or written authorization to use their personal and health
             data

          -  Patients who started Kaletra treatment after study agreement was in place

        Exclusion Criteria:

          -  Patients with known hypersensitivity to lopinavir, ritonavir or any excipients of the
             Kaletra tablet

          -  Patients who were being treated or will be treated with drugs that are contraindicated
             with Kaletra

          -  Patients who have been treated with Kaletra

          -  Patients participating in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SoRa Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Ltd.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <results_first_submitted>October 30, 2015</results_first_submitted>
  <results_first_submitted_qc>January 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2016</results_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postmarketing Drug Surveillance</keyword>
  <keyword>HIV-1 infection</keyword>
  <keyword>Kaletra</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Main Surveillance</title>
          <description>The safety population included all participants who received at least one dose of Kaletra, and the effectiveness population included all participants who received Kaletra treatment for at least 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Long-term Surveillance</title>
          <description>The safety population included all participants who received Kaletra for more than 24 weeks, and the effectiveness population included all participants who received Kaletra treatment for at least 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Surveillance: Safety Group</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="595"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="580"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Violation of inclusion/exclusion crit.</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of the use/dosage</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Main Surveillance: Effectiveness Group</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="580"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow-up at 24 Â±4 wks</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No viral load data at 24 Â±4 wks</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administration of Kaletra &lt;24 wks</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Surveillance: Safety Group</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="595"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="479"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Violation of inclusion/exclusion crit.</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of the dosage</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administration of Kaletra &lt;20 wks</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Surveillance: Effectiveness Gr</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="479"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="377"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow-up at 48 Â±4 wks</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No viral load data at 48 Â±4 wks</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administration of Kaletra &lt;48 wks</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>The main surveillance safety population included all participants who received at least one dose of Kaletra. The long-term surveillance safety population included participants who received Kaletra for more than 24 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="580"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Main Surveillance n= 580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-term Surveillance n=479</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Main Surveillance Females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Surveillance Males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-Term Surveillance Females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-Term Surveillance Males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Adverse events were recorded during the 48-week surveillance period and until 30 days following the last dose.</description>
        <time_frame>From the start of treatment until 30 days after the last dose, up to 52 weeks</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Main Surveillance</title>
            <description>All participants who received at least one dose of Kaletra</description>
          </group>
          <group group_id="O2">
            <title>Long-term Surveillance</title>
            <description>Participants who received Kaletra for more than 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Adverse events were recorded during the 48-week surveillance period and until 30 days following the last dose.</description>
          <population>Participants with available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="580"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Interrupted or Discontinued Kaletra Treatment</title>
        <description>At 24 and 48 weeks after initiation of Kaletra treatment or upon permanent discontinuation of Kaletra treatment, the investigator documented Kaletra status (on-going, permanently discontinued, lost to follow-up, etc).</description>
        <time_frame>Weeks 24 and 48 after initiation of Kaletra treatment or upon permanent discontinuation of Kaletra treatment</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Main Surveillance</title>
            <description>All participants who received at least one dose of Kaletra</description>
          </group>
          <group group_id="O2">
            <title>Long-term Surveillance</title>
            <description>Participants who received Kaletra for more than 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Interrupted or Discontinued Kaletra Treatment</title>
          <description>At 24 and 48 weeks after initiation of Kaletra treatment or upon permanent discontinuation of Kaletra treatment, the investigator documented Kaletra status (on-going, permanently discontinued, lost to follow-up, etc).</description>
          <population>Participants with available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="580"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Viral Load Below 400 Copies/mL</title>
        <description>Blood samples were obtained from participants 24 weeks after the start of Kaletra treatment, and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Main Surveillance</title>
            <description>All participants who received Kaletra treatment for at least 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Load Below 400 Copies/mL</title>
          <description>Blood samples were obtained from participants 24 weeks after the start of Kaletra treatment, and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels.</description>
          <population>Participants with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Viral Load</title>
        <description>This variable, change from baseline in viral load, was not included in the final protocol. Therefore, these data were not calculated.</description>
        <time_frame>Week 24 &amp; 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Main Surveillance</title>
            <description>All participants who received at least one dose of Kaletra</description>
          </group>
          <group group_id="O2">
            <title>Long-term Surveillance</title>
            <description>Participants who received Kaletra for more than 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Viral Load</title>
          <description>This variable, change from baseline in viral load, was not included in the final protocol. Therefore, these data were not calculated.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Counts</title>
        <description>Blood samples were obtained from participants at baseline, 24, and 48 weeks after the start of Kaletra treatment and analyzed for CD4 cell counts. Change in CD4 cell counts in the main surveillance population was calculated by subtracting the value at baseline from the value at 24 weeks. Change in CD4 cell counts in the long-term surveillance population was calculated by subtracting the value at baseline from the value at 48 weeks.</description>
        <time_frame>From baseline to Weeks 24 and 48</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Main Surveillance</title>
            <description>All participants who received Kaletra treatment for at least 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Long-term Surveillance</title>
            <description>All participants who received Kaletra treatment for at least 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Counts</title>
          <description>Blood samples were obtained from participants at baseline, 24, and 48 weeks after the start of Kaletra treatment and analyzed for CD4 cell counts. Change in CD4 cell counts in the main surveillance population was calculated by subtracting the value at baseline from the value at 24 weeks. Change in CD4 cell counts in the long-term surveillance population was calculated by subtracting the value at baseline from the value at 48 weeks.</description>
          <population>Participants with available data</population>
          <units>cells/mmË3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.47" spread="144.28"/>
                    <measurement group_id="O2" value="170.47" spread="159.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>CD4 cell counts at 24 weeks as compared to baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4 cell counts at 48 weeks as compared to baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Confirmed Viral Resistance</title>
        <description>Blood samples were obtained from participants at initiation of Kaletra treatment and follow up visits through weeks 24 and 48 and analyzed for genotypic viral resistance.</description>
        <time_frame>From baseline through weeks 24 and 48</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Main Surveillance</title>
            <description>All participants who received Kaletra treatment for at least 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Long-term Surveillance</title>
            <description>All participants who received Kaletra treatment for at least 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Confirmed Viral Resistance</title>
          <description>Blood samples were obtained from participants at initiation of Kaletra treatment and follow up visits through weeks 24 and 48 and analyzed for genotypic viral resistance.</description>
          <population>Participants with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51"/>
                    <measurement group_id="O2" value="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time to Treatment Failure</title>
        <description>Blood samples were obtained from participants at initiation of Kaletra treatment and at follow up visits through weeks 24 and 48 and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels. Treatment failure was defined as HIV RNA level &gt; 400 copies/mL at week 24 and HIV RNA level &gt; 50 copies/mL at week 48.</description>
        <time_frame>From baseline through weeks 24 and 48</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Main Surveillance</title>
            <description>All participants who received Kaletra treatment for at least 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Long-term Surveillance</title>
            <description>All participants who received Kaletra treatment for at least 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to Treatment Failure</title>
          <description>Blood samples were obtained from participants at initiation of Kaletra treatment and at follow up visits through weeks 24 and 48 and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels. Treatment failure was defined as HIV RNA level &gt; 400 copies/mL at week 24 and HIV RNA level &gt; 50 copies/mL at week 48.</description>
          <population>Participants with available data</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.97" spread="3.45"/>
                    <measurement group_id="O2" value="410.8" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Viral Load Below 50 Copies/mL</title>
        <description>Blood samples were obtained from participants 48 weeks after the start of Kaletra treatment, and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term Surveillance</title>
            <description>All participants who received Kaletra treatment for at least 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Load Below 50 Copies/mL</title>
          <description>Blood samples were obtained from participants 48 weeks after the start of Kaletra treatment, and analyzed for human immunodeficiency virus-1 (HIV-1) RNA levels.</description>
          <population>Participants with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of treatment until 30 days after the last dose, up to 52 weeks</time_frame>
      <desc>Adverse event(s) details, including the type of adverse event(s), onset/end date, severity, action taken, and relationship to the drug and the investigatorâs view on the adverse event(s) (whether it was related to the drug or not) were recorded during the 48-week surveillance period and until 30 days following the last dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Main Surveillance</title>
          <description>All participants who received at least one dose of Kaletra</description>
        </group>
        <group group_id="E2">
          <title>Long-term Surveillance</title>
          <description>Participants who received Kaletra for more than 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Spleen tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="580"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Information</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

